Activating mutations cluster in the "molecular brake" regions of protein kinases and do not associate with conserved or catalytic residues

Human Mutation

Volumn 35, Issue 3, 2014, Pages 318-328

  Molina Vila, Miguel A ^a   Nabau Moretó, Nuria ^b   Tornador, Cristian ^c,d   Sabnis, Amit J ^e,f   Rosell, Rafael ^a   Estivill, Xavier ^c,d   Bivona, Trever G ^f   Marino Buslje, Cristina ^g  

^a INSTITUT UNIVERSITARI DEXEUS   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^d UNIVERSITAT POMPEU FABRA   (Spain)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g FUNDACIÓN INSTITUTO LELOIR   (Argentina)

Author keywords

Activating mutations; Cancer; Driver mutations; Protein kinases; Proto onocogenes; Targeted therapies

Indexed keywords

PROTEIN KINASE;

ARTICLE; BIOINFORMATICS; CATALYSIS; ENZYME ACTIVITY; GENE MUTATION; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SEQUENCE ALIGNMENT;

ACTIVATING MUTATIONS; CANCER; DRIVER MUTATIONS; PROTEIN KINASES; PROTO-ONOCOGENES; TARGETED THERAPIES;

CATALYTIC DOMAIN; CLUSTER ANALYSIS; COMPUTATIONAL BIOLOGY; HUMANS; MODELS, MOLECULAR; MULTIGENE FAMILY; MUTATION, MISSENSE; NEOPLASMS; PHOSPHORYLATION; PROTEIN CONFORMATION; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, EPHA7; SEQUENCE ALIGNMENT;

EID: 84893981380     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.22493     Document Type: Article

References (48)

1. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, et al. 2010. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:596-599.
2. Chan P, Ilangumaran S, La Rose J, Chakrabartty A, Rottapel R. 2003. Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region. Mol Cell Biol 23:3067-3078.
3. Chen H, Ma J, Li W, Eliseenkova AV, Xu C, Neubert TA, Miller WT, Mohammadi M. 2007. A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol Cell 27:717-730.
4. Chen H, Huang Z, Dutta K, Blais S, Neubert TA, Li X, Cowburn D, Traaseth NJ, Mohammadi M. 2013. Cracking the molecular origin of intrinsic tyrosine kinase activity through analysis of pathogenic gain-of-function mutations. Cell Rep 25:376-384.
5. Cover TM, Thomas JA. 1991. Elements of information theory. New York, NY: Wiley-Interscience.
6. Consortium TU. 2012. Reorganizing the protein space at the Universal Protein Resource (UniProt). Nucleic Acids Res 40:D71-D75.
7. Croce CM. 2008. Oncogenes and cancer. N Engl J Med 358:502-511.
8. Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, Pazdur R. 2002. Approval summary: Imatinib Mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8:3034-3038.
9. Dixit A, Yi L, Gowthaman R, Torkamani A, Schork N, Verkhivker G. 2009. Sequence and structure signatures of cancer mutation hotspots in protein kinases. PLoS One 4(10):e7485-e7493.
10. Fearon ER, Vogelstein B. 1990. A genetic model for colorectal tumorigenesis. Cell 61:759-767.
11. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, Jia M, Shepherd R, Leung K, Menzies A, Teague JW, Campbell PJ, et al. 2011. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in cancer. Nucleic Acids Res 39:D945-D950.
12. Fröhling S, Scholl C, Levine RL, Loriaux M, Boggon TJ, Bernard OA, Berger R, Döhner H, Döhner K, Ebert BL, Teckie S, Golub TR, et al. 2007. Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell 12:501-513.
13. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, Stratton MR. 2004. A census of human cancer genes. Nat Rev Cancer 4:177-183.
14. Gonzalez-Perez A, Deu-Pons J, Lopez-Bigas N. 2012. Improving the prediction of the functional impact of cancer mutations by baseline tolerance transformation. Genome Med 4:89.
15. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, et al. 2007. Patterns of somatic mutation in human cancer genomes. Nature 446:153-158.
16. Griffith J, Black J, Faerman C, Swenson L, Wynn M, Lu F, Lippke J, Saxena K. 2004. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol Cell 13:169-781.
17. Hanks S, Hunter T. 1995. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J 9:576-596.
18. Hashimoto K, Rogozin IB, Panchenko AR. 2012. Oncogenic potential is related to activating effect of cancer single and double somatic mutations in receptor tyrosine kinases. Human Mut 33:1566-1575.
19. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martín-Algarra S, Karaszewska B, et al. 2012. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380:358-365.
20. Holmberg J, Clarke DL, Frisen J. 2000. Regulation of repulsion versus adhesion by different splice forms of an Eph receptor. Nature 408:203-206.
21. Kan Z, Jaiswal BS, Stinson J, Janakiraman V, Bhatt D, Stern HM, Yue P, Haverty PM, Bourgon R, Zheng J, Moorhead M, Chaudhuri S, et al. 2010. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466:869-873.
22. Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, McTigue MA, Alitalo K, Finegold DN. 2000. Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema. Nat Genet 25:153-159.
23. Lee W, Zhang Y, Mukhyala K, Lazarus R, Zhang Z. 2009. Bi-directional SIFT predicts a subset of activating mutations. PLoS One 4:e8311-e8318.
24. Lei M, Lu W, Meng W, Parrini MC, Eck MJ, Mayer BJ, Harrison SC. 2000. Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch. Cell 102:387-389.
25. Lei M, Robinson MA, Harrison SC. 2005. The active conformation of the PAK1 kinase domain. Structure 13:769-778.
26. Loriaux MM, Levine RL, Tyner JW, Fröhling S, Scholl C, Stoffregen EP, Wernig G, Erickson H, Eide CA, Berger R, Bernard OA, Griffin JD, et al. 2008. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood 111:4788-4796.
27. Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S. 2002. The protein kinase complement of the human genome. Science 298:1912-1934.
28. Marino-Buslje C, Teppa E, Di Doménico T, Delfino JM, Nielsen M. 2010. Networks of high mutual information define the structural proximity of catalytic sites: implications for catalytic residue identification. PLoS Comput Biol 6:e1000978.
29. Oricchio E, Nanjangud G, Wolfe AL, Schatz JH, Mavrakis KJ, Jiang M, Liu X, Bruno J, Heguy A, Olshen AB, Socci ND, Teruya-Feldstein J, et al. 2011. The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell 147:554-564.
30. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, et al. 2004. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306-13311.
31. Pasquale, E. 2010. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 10:165-180.
32. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. 2004. UCSF chimera-a visualization system for exploratory research and analysis. J Comp Chem 25:1605-1612.
33. Pollock PM, Gartside MG, Dejeza LC, Powell MA, Mallon MA, Davies H, Mohammadi M, Futreal PA, Stratton MR, Trent JM, Goodfellow PJ. 2007. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 26:7158-7162.
34. Porter C, Bartlett G, Thornton J. 2004. The Catalytic Site Atlas: a resource of catalytic sites and residues identified in enzymes using structural data. Nucleic Acids Res 32:D129-D133.
35. Puente XS, Pinyol M, Quesada V, Conde L, Ordóñez GR, Villamor N, Escaramis G, Jares P, Beà S, González-Díaz M, Bassaganyas L, Baumann T, et al. 2011. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475:101-105.
36. Punta M, Coggill PC, Eberhardt RY, Mistry J, Tate J, Boursnell C, Pang N, Forslund K, Ceric G, Clements J, Heger A, Holm L, et al. 2012. The Pfam protein families database. Nucleic Acids Res 40:D290-D301.
37. Reva B, Antipin Y, Sander C. 2011. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 39:e118.
38. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B. 2009. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 361:958-967.
39. Shan Y, Eastwood MP, Zhang X, Kim ET, Arkhipov A, Dror RO, Jumper J, Kuriyan J, Shaw DE. 2012. Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization. Cell 149:860-870.
40. Shi Z, Moult J. 2011. Structural and functional impact of cancer-related missense somatic mutations. J Mol Biol 413:495-512.
41. Siddiqui M, Scott L. 2007. Imatinib: a review of its use in the management of gastrointestinal stromal tumours. Drugs 67:805-820.
42. Shihab HA, Gough J, Cooper DN, Stenson PD, Barker GL, Edwards KJ, Day IN, Gaunt TR. 2013. Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden Markov models. Human Mut 34:57-65.
43. Taly JF, Magis C, Bussotti G, Chang JM, Di Tommaso P, Erb I, Espinosa-Carrasco J, Kemena C, Notredame C. 2011. Using the T-Coffee package to build multiple sequence alignments of protein, RNA, DNA sequences and 3D structures. Nat Protocol 6:1669-1682.
44. Torkamani A, Schork NJ. 2008a. Prediction of cancer driver mutations in protein kinases. Cancer Res 68:1675-1682.
45. Torkamani A, Kannan N, Taylor SS, Schork NJ. 2008b. Congenital disease SNPs target lineage specific structural elements in protein kinases. Proc Natl Acad Sci USA 105:9011-9016.
46. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, et al. 2007. The genomic landscapes of human breast and colorectal cancers. Science 318:1108-1113.
47. Zhang X, Gureasko J, Shen K, Cole P, Kuriyan J. 2006. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125:1137-1149.
48. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, Lu C, Chen SC, et al. 2012. The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481:157-163.